NAD+ Microneedling for Melasma: Topical Skinbooster Efficacy

SNIPPET: A new single-centre case series published in Aesthetic Plastic Surgery (March 2026) found that microneedling-assisted topical NAD+ delivery reduced melasma severity (MASI scores) by 59.2% over 21 weeks in 36 Korean women, with 83.3% showing clinical improvement and only transient side effects — positioning direct NAD+ skin delivery as a potential alternative to hydroquinone-based treatments.

THE PROTOHUMAN PERSPECTIVE#

NAD+ has been the longevity community's favourite molecule for half a decade now, but almost all the attention has gone to oral precursors — NMN, NR, the usual suspects. This study flips the delivery route entirely. Instead of hoping systemic NAD+ levels trickle down to benefit skin, the researchers drove the coenzyme directly into the dermis via microneedling. That's a fundamentally different proposition.

Why should you care? Melasma affects up to 33% of certain populations, and the current gold standard — hydroquinone — comes with a side-effect profile that makes long-term use questionable. If NAD+ can be delivered locally to restore mitochondrial bioenergetics in dysfunctional melanocytes, we're looking at a mechanism that doesn't just bleach pigment but potentially addresses the cellular dysfunction driving it. That's the shift worth watching: from cosmetic suppression to cellular repair. It's early data — Level IV evidence, no control group — but the mechanistic logic is sound, and the safety profile was clean. For anyone tracking the NAD+ space, this is a new vector.

THE SCIENCE#

NAD+ and Melanocyte Dysfunction: The Mechanistic Case#

Let me set the stage. Melasma isn't just a pigmentation problem — it's increasingly understood as a disorder of dysfunctional melanocytes operating under oxidative stress, with impaired mitochondrial efficiency and disrupted cellular signalling. NAD+ sits at the centre of this web. It's the primary substrate for sirtuins (SIRT1–SIRT7), which regulate everything from DNA repair to autophagy pathways to inflammatory gene expression ^[1]. When NAD+ levels drop — as they do with ageing and UV exposure — sirtuin activity declines, oxidative damage accumulates, and melanocytes behave erratically.

The study published in Aesthetic Plastic Surgery by researchers at a single Korean centre used a microneedling therapy system (MTS) to deliver a sterile NAD+ booster (Sihler N, Sihler Inc., Korea) intradermally ^[1]. Thirty-six Korean women with mixed-type melasma received five sessions at three-week intervals over 21 weeks.

The primary outcome was clear: mean MASI score dropped from 16.8 ± 5.2 to 6.9 ± 3.1 (p < 0.001), a 59.2% reduction ^[1]. Independent blinded dermatologists rated 83.3% of patients as demonstrating clinical improvement on the Global Aesthetic Improvement Scale. Side effects were limited to transient erythema and oedema — both resolving within 48 hours.

Look, those numbers are solid for a case series. But I need to flag the obvious: there's no control arm. No vehicle-only microneedling group. Microneedling alone has documented efficacy for melasma, so we genuinely don't know how much of that 59.2% is the NAD+ versus the needles. The authors acknowledge this, calling for split-face and vehicle-controlled trials. I'd want to see exactly that before getting too excited.

Why Intradermal Delivery Changes the Equation#

Here's where it gets interesting from a biohacking perspective. Oral NAD+ precursors face significant bioavailability challenges — first-pass metabolism, gut degradation, variable tissue distribution. NAD+ itself is a large, charged molecule that doesn't cross intact skin. Microneedling solves that problem mechanically, creating transient microchannels that allow direct dermal penetration.

The implication is that you can achieve locally high NAD+ concentrations in the target tissue without needing to flood systemic circulation. This is more efficient and potentially avoids some of the dose-dependent gastrointestinal issues reported with high-dose oral NMN and NR supplementation.

The Comparator Landscape: Niacinamide, Tranexamic Acid, and Hydroquinone#

Wait, let me be more precise here — because NAD+ and niacinamide (nicotinamide) are related but not identical. Niacinamide is a precursor that the body converts into NAD+ through the salvage pathway via NAMPT. Several recent trials have tested niacinamide-containing topicals against hydroquinone, and the results contextualize this new NAD+ study.

Rocio et al. (2025) conducted a randomized, investigator-blind study comparing a serum containing 5% niacinamide, 1% tranexamic acid, and vitamin C ("Serum B3") against 4% hydroquinone in 60 women with facial melasma ^[2]. Both treatments produced significant MASI reductions after three months (p < 0.001), with no significant difference between groups. But the niacinamide serum showed better skin hydration, barrier function, and tolerability.

Similarly, a randomized, double-blind trial by researchers in Iran compared niosomal and conventional tranexamic acid/niacinamide creams against 4% hydroquinone in 99 melasma patients ^[3]. All three groups showed considerable MASI reductions, but the hydroquinone group experienced more adverse reactions and relapse.

The pattern is consistent: niacinamide-based approaches match hydroquinone for efficacy while avoiding its side-effect baggage. The new NAD+ microneedling study extends this logic by bypassing the precursor conversion step entirely and delivering the active coenzyme directly.

The Limitation I Can't Ignore#

This is Level IV evidence — the lowest rung on the evidence hierarchy that still counts as clinical data. No randomization, no blinding, no control group, single centre, 36 patients. The product used (Sihler N) is a branded commercial formulation, and while the study doesn't appear industry-funded based on the available abstract, the use of a specific branded product always warrants scrutiny.

I'm also less convinced by the 21-week endpoint without follow-up data. Melasma's defining characteristic is recurrence. Showing a 59.2% reduction is meaningful only if it holds at 6 or 12 months post-treatment. The study doesn't address this.

COMPARISON TABLE#

THE PROTOCOL#

Based on the study methodology and supporting evidence, here's a practical framework. Note: this protocol requires clinical supervision — do not attempt unsupervised microneedling with active compounds.

1. Consultation and skin assessment. Have a dermatologist confirm mixed-type or dermal melasma diagnosis using Wood's lamp examination. Establish baseline MASI scoring and photographic documentation. Fitzpatrick skin types III–V appear to be the most relevant population based on the study cohort.

2. Pre-treatment preparation (2 weeks prior). Discontinue retinoids, chemical exfoliants, and any photosensitizing agents at least 14 days before the first session. Begin broad-spectrum SPF 50+ sunscreen (mineral-based preferred) daily. This is non-negotiable — UV exposure during treatment will undermine results.

3. Microneedling + NAD+ application session. The clinician performs MTS at appropriate depth for melasma (typically 0.5–1.0 mm). Immediately following microneedling, the sterile NAD+ booster is applied topically to the treated area. The microchannels created by MTS allow transdermal penetration of the NAD+ molecule. Each session takes approximately 30–45 minutes.

4. Post-session care (48 hours). Expect transient erythema and mild oedema — this is normal and should resolve within 48 hours. Avoid makeup, active skincare ingredients, and direct sun exposure for at least 24–48 hours post-treatment. Apply a gentle, fragrance-free moisturiser and continue SPF 50+ religiously.

5. Treatment schedule. Repeat sessions every three weeks for a total of five sessions (21-week protocol). Do not compress the interval — the three-week spacing allows adequate skin recovery and collagen remodelling between sessions.

6. Maintenance and monitoring. After completing the five-session course, reassess MASI scores and compare with baseline photography. Given melasma's recurrence tendency, consider maintenance sessions every 8–12 weeks, though this specific protocol hasn't been studied for maintenance frequency. Continue daily SPF 50+ indefinitely.

7. Adjunctive support (optional). Based on the comparative data from Rocio et al. ^[2], using a niacinamide 5% + tranexamic acid serum on non-treatment days may provide complementary NAD+ precursor support and melanosome transfer inhibition between sessions.

VERDICT#

Score: 6/10

The mechanistic logic is genuinely interesting — intradermal NAD+ delivery targeting cellular dysfunction rather than just suppressing pigment production represents a conceptually superior approach. The 59.2% MASI reduction is clinically meaningful. But I can't score this higher when the evidence is a single uncontrolled case series of 36 patients with no follow-up data on recurrence. Microneedling alone improves melasma, so the NAD+ contribution is genuinely uncertain. The branded product and lack of a vehicle control raise additional questions. I want to see the split-face RCT the authors themselves called for. Until then, this is a hypothesis worth pursuing, not a protocol worth adopting over established options. If you're already doing microneedling for melasma and have access to this product, the risk profile is minimal. But swapping out proven treatments for this based on current evidence? Not yet.